Drug combinations can improve drug resistance by targeting multiple pathways or mechanisms simultaneously, making it more difficult for the cancer cells to develop resistance.
Liposomal drug delivery systems are unique formulations that have gained significant attention in recent years due to their ability to enhance the pharmacokinetics and targeting of certain medications.
Federal regulations require that applicable clinical trials and NIH-funded clinical trials be registered no later than 21 days after enrollment of the first participant.
Mucoadhesive drug delivery systems (MDDS) are designed to enhance the residence time of a drug at a specific site in the body, primarily on mucosal surfaces.